Recruiting PHASE3 INTERVENTIONAL 2-arm NCT03949049

Citicoline as Neuroprotector in Neonates Exposed to Hypoxia

Efficacy of Citicoline as Neuroprotector in Neonates Exposed to Hypoxia: A Randomized Controlled Trial

Sponsor: Sherief Abd-Elsalam

Updated 4 times since 2019 Last updated: May 24, 2019 Started: Feb 1, 2019 Primary completion: Dec 1, 2029 Completion: Dec 1, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03949049, this PHASE3 trial focuses on Neonatal Hypoxia and remains actively recruiting participants. Sponsored by Sherief Abd-Elsalam, it has been updated 4 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jan 2021 — Jul 2024 [monthly]

Recruiting PHASE3
Jun 2019 — Jan 2021 [monthly]

Recruiting PHASE3

First recorded

Feb 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sherief Abd-Elsalam

Data source: Tanta University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cairo, Egypt